Assessment of Dengue Virus Inactivation in Random Donor Platelets Using Amotosalen and Ultraviolet A Illumination

Overview

Journal Asian J Transfus Sci

Specialty Hematology

Date 2022 Oct 6

PMID 36199414

Authors

Ankit Kumar

Aseem Kumar Tiwari

Satendra Kumar

Ashutosh Biswas

Gurpreet Singh

Kabita Chatterjee

Sourit Chakroborty

Sujatha Sunil

Affiliations

Soon will be listed here.

Abstract

Objectives: The study objective was evaluation of amotosalen and ultraviolet A (UVA) illumination-based inactivation of dengue virus (DENV) in blood platelets.

Materials And Methods: Whole blood was collected from healthy donors and platelet concentrates were prepared at a tertiary care hospital in Gurugram, India. Platelet units collected from five blood group matched individuals were pooled and spiked with DENV. The spiked platelet units were subjected to amotosalen treatment followed by UVA illumination, to evaluate the efficiency of this method for viral inactivation. The treated platelet units were evaluated for the presence of infectious DENV. Amotosalen levels were quantified in the treated samples using high-performance liquid chromatography.

Results: The presence of replicating DENV was not observed in spiked platelet units treated with amotosalen and UVA illumination, whereas untreated units contained actively replicating DENV. Amotosalen levels were found to be in the permissible range after photochemical inactivation.

Conclusions: Amotosalen/UVA pathogen inactivation treatment showed efficient inactivation of DENV in platelet components. Therefore, it seems to be a promising method for mitigating the risk of dengue transmission through transfusion of potentially contaminated platelet components in dengue-endemic countries such as India.

References

Tice R, Gatehouse D, Kirkland D, Speit G . The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutat Res. 2007; 630(1-2):50-68. DOI: 10.1016/j.mrgentox.2007.02.008. View

Aubry M, Richard V, Green J, Broult J, Musso D . Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2015; 56(1):33-40. DOI: 10.1111/trf.13271. View

Seghatchian J, Tolksdorf F . Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apher Sci. 2012; 46(2):221-9. DOI: 10.1016/j.transci.2012.01.008. View

Musso D, Richard V, Broult J, Cao-Lormeau V . Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2014; 54(11):2924-30. DOI: 10.1111/trf.12713. View

Makroo R, Sardana R, Mediratta L, Butta H, Thakur U, Agrawal S . Evaluation of bacterial inactivation in random donor platelets and single-donor apheresis platelets by the INTERCEPT blood system. Asian J Transfus Sci. 2019; 12(2):146-153. PMC: 6327773. DOI: 10.4103/ajts.AJTS_87_17. View

Walsh J, Purcell R, Morrow A, Chanock R, Schmidt P . Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA. 1970; 211(2):261-5. DOI: 10.1001/jama.211.2.261. View

Aubry M, Laughhunn A, Santa Maria F, Lanteri M, Stassinopoulos A, Musso D . Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione. Transfusion. 2017; 57(12):2888-2896. DOI: 10.1111/trf.14318. View

Roback J, Conlan M, Drew W, Ljungman P, Nichols W, Preiksaitis J . The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev. 2005; 20(1):45-56. DOI: 10.1016/j.tmrv.2005.08.004. View

Ghoshal K, Bhattacharyya M . Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. ScientificWorldJournal. 2014; 2014:781857. PMC: 3960550. DOI: 10.1155/2014/781857. View

10.

Ciaravino V . Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Semin Hematol. 2001; 38(4 Suppl 11):12-9. DOI: 10.1016/s0037-1963(01)90119-2. View

11.

Tambyah P, Koay E, Poon M, Lin R, Ong B . Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med. 2008; 359(14):1526-7. DOI: 10.1056/NEJMc0708673. View

12.

Laughhunn A, Huang Y, Vanlandingham D, Lanteri M, Stassinopoulos A . Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione. Transfusion. 2018; 58(3):748-757. DOI: 10.1111/trf.14442. View

13.

Tsetsarkin K, Sampson-Johannes A, Sawyer L, Kinsey J, Higgs S, Vanlandingham D . Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light. Am J Trop Med Hyg. 2013; 88(6):1163-9. PMC: 3752818. DOI: 10.4269/ajtmh.12-0603. View

14.

Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A . A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion. 2009; 49(12):2612-24. DOI: 10.1111/j.1537-2995.2009.02334.x. View

15.

Schubert P, Johnson L, Marks D, Devine D . Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets. Front Med (Lausanne). 2018; 5:129. PMC: 5949320. DOI: 10.3389/fmed.2018.00129. View

16.

Chuang V, Wong T, Leung Y, Ma E, Law Y, Tsang O . Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J. 2008; 14(3):170-7. View

17.

Irsch J, Seghatchian J . Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects. Transfus Apher Sci. 2015; 52(2):240-4. DOI: 10.1016/j.transci.2015.02.013. View

18.

Irsch J, Lin L . Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™. Transfus Med Hemother. 2011; 38(1):19-31. PMC: 3132977. DOI: 10.1159/000323937. View

19.

Lin L, Conlan M, Tessman J, Cimino G, Porter S . Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion. 2005; 45(10):1610-20. DOI: 10.1111/j.1537-2995.2005.00554.x. View

20.

Peterman T, Lui K, Lawrence D, Allen J . Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion. 1987; 27(5):371-4. DOI: 10.1046/j.1537-2995.1987.27587320525.x. View